Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Initial experience with paclitaxel-coated stents.

Eberhard Grube1, Lutz Büllesfeld

  • 1Heart-Center Siegburg, Ringstrasse 49, 53721 Siegburg, Germany. GrubeE@aol.com

Journal of Interventional Cardiology
|December 13, 2002
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Clinical Impact of Myocardium at Risk in Transcatheter Aortic Valve Implantation.

Circulation. Cardiovascular interventions·2026
Same author

Three-Year Outcomes With a Supra-Annular, Self-Expanding Bioprosthesis and a Pericardial Wrap-The FORWARD PRO Study.

Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions·2024
Same author

Findings from transoesophageal echocardiographic follow-up after mitral transcatheter edge-to-edge repair.

EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology·2024
Same author

Transcatheter Aortic Valve Replacement in Patients at High Risk of Coronary Obstruction.

Journal of the Society for Cardiovascular Angiography & Interventions·2024
Same author

Impact of the COVID-19 Pandemic on Global TAVR Activity: The COVID-TAVI Study.

JACC. Cardiovascular interventions·2024
Same author

Cerebral embolic protection during transcatheter heart interventions.

EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology·2023
Same journal

Meta-Analysis of Randomized Trials: Efficacy and Safety of Colchicine for Secondary Prevention of Cardiovascular Disease.

Journal of interventional cardiology·2024
Same journal

Effect of Neutrophil-to-Lymphocyte Ratio on Post-TAVR Mortality and Periprocedural Pulmonary Hypertension.

Journal of interventional cardiology·2024
Same journal

Examining the Outcomes of Hybrid Coronary Revascularization in Acute STEMI Patients from 2015 to 2022.

Journal of interventional cardiology·2024
Same journal

Clinical and Laboratory Predictors of Long-Term Outcomes after Catheter Ablation for a Ventricular Electrical Storm.

Journal of interventional cardiology·2024
Same journal

Comparison of Ticagrelor and Clopidogrel in Elective Coronary Stenting: A Double Blind Randomized Clinical Trial.

Journal of interventional cardiology·2024
Same journal

Mitral Valve Transcatheter Edge-to-Edge Repair Volumes and Trends.

Journal of interventional cardiology·2023
See all related articles

Drug-eluting stents deliver immunosuppressive agents to inhibit in-stent restenosis. Paclitaxel and sirolimus stents show significant reduction in restenosis, though safety profiles require further evaluation.

Area of Science:

  • Cardiovascular Medicine
  • Interventional Cardiology
  • Biomaterials Science

Background:

  • Drug-eluting stents (DES) represent a novel approach to prevent in-stent restenosis.
  • Various immunosuppressive and antiproliferative agents are being investigated for local delivery via stents.
  • In-stent restenosis remains a significant challenge in coronary interventions.

Purpose of the Study:

  • To evaluate the efficacy and safety of drug-eluting stents in inhibiting in-stent restenosis.
  • To review clinical trial data on different drug-eluting stent platforms and agents.
  • To assess the impact of drug dosage and delivery duration on outcomes.

Main Methods:

  • Review of clinical trials including SCORE, TAXUS, ELUTES, ASPECT, RAVEL, and SIRIUS.

Related Experiment Videos

  • Analysis of outcomes such as in-stent restenosis rates, neointimal proliferation, and major adverse cardiac events (MACE).
  • Comparison of paclitaxel-eluting stents and sirolimus-eluting stents.

    • Main Results:

    • Paclitaxel-eluting stents demonstrated significant reduction in restenosis (e.g., 83% in SCORE trial) but showed higher MACE rates in early studies.
    • Sirolimus-eluting stents (RAVEL, SIRIUS trials) confirmed beneficial reduction in renarrowing without major adverse effects.
    • Dose-response relationships were observed for paclitaxel-coated stents, indicating optimal dosage is crucial.

    Conclusions:

    • Drug-eluting stents are highly effective in reducing in-stent restenosis and neointimal proliferation.
    • While promising, ongoing evaluation is needed for drug toxicity, optimal dosing, and endothelial healing.
    • Current clinical experience supports the benefit of drug-coated stents in coronary lesion treatment.